Zoetis Inc. (NYSE:ZTS) Shares Acquired by Rathbones Group PLC

Rathbones Group PLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 8.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 435,999 shares of the company’s stock after acquiring an additional 33,871 shares during the period. Rathbones Group PLC owned approximately 0.10% of Zoetis worth $71,037,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the period. Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in shares of Zoetis in the fourth quarter valued at approximately $44,000. Finally, Asset Planning Inc acquired a new position in shares of Zoetis during the 4th quarter worth approximately $58,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $151.76 on Monday. Zoetis Inc. has a 52 week low of $144.69 and a 52 week high of $200.33. The company has a fifty day simple moving average of $165.71 and a two-hundred day simple moving average of $173.26. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $67.96 billion, a price-to-earnings ratio of 27.74, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.32%. Zoetis’s dividend payout ratio is currently 36.56%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ZTS. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Piper Sandler upped their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Barclays lifted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $215.90.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.